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Abstract 
 
Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease lacking 
effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-
shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-
inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. Aim: To 
evaluate the safety and efficacy of 3 doses of oral norUDCA (500 mg/d, 1000 mg/d or 
1500 mg/d) compared with placebo in PSC in a RCT including 38 centers from 
12 European countries. Methods: 161 PSC patients without concomitant UDCA therapy 
and with elevated serum alkaline phosphatase (ALP) levels were randomized for 12-
weeks treatment followed by a 4-weeks follow-up. Primary efficacy endpoint was the 
mean relative change (%) in ALP levels between baseline and end-of-treatment visit. 
Results: norUDCA reduced ALP levels by -12.3%, -17.3%, and -26.0% in the 500, 1000, 
and 1500 mg/d groups (p=0.029, =0.003, and <0.0001 when compared to placebo), 
respectively, while a +1.2% increase was observed in the placebo group. Similar dose-
dependent results were found for secondary endpoints, such as ALT, AST, γ-GT, or the 
rate of patients achieving ALP levels < 1.5x ULN. Serious adverse events occurred in 7 in 
the 500 mg/d-, 5 in the 1000 mg/d-, 2 in the 1500 mg/d-group, and 3 in the placebo 
group, respectively. There was no difference in reported pruritus between treatment 
and placebo groups. Conclusions: norUDCA significantly reduced ALP values dose 
dependently in all treatment arms. Safety profile of norUDCA was excellent and 
comparable to placebo. Consequently, a phase-3 trial of norUDCA in PSC appears 
justified.  
 
ClinicalTrials.gov number: NCT01755507 
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Lay summary 
Effective medical therapy for primary sclerosing cholangitis (PSC) is urgently needed. In 
this phase II clinical study, a side chain shortened derivative of ursodeoxycholic acid, 
norursodeoxycholic acid (norUDCA) significantly reduced serum alkaline phosphatase 
levels within 12 weeks as important surrogate marker in PSC in a dose-dependent 
manner. Importantly, norUDCA showed a favorable safety profile, which was similar to 
placebo. The use of norUDCA in PSC patients is promising and will be further evaluated 
in a phase III clinical study. 
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Introduction 
 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown 
etiology characterized by a chronic inflammatory and fibro-obliterative destruction of 
extra-, and intrahepatic bile ducts [1]. Currently there is no medical therapy with proven 
benefit on PSC patients’ survival available and the list of drugs tested negative for PSC 
treatment is long comprising azathioprine, cyclosporine, methotrexate, tacrolimus, 
penicillamine, cholchicine, and infliximab [2]. Consequently, liver transplantation is the 
only treatment option for PSC patients with end-stage liver disease. The use of 
ursodeoxycholic acid (UDCA) in the treatment of PSC is highly controversial [3,[4,[5]. 
Numerous studies showed biochemical or histological improvement, but failed to 
demonstrate significant differences in death rates, transplant-free survival, or 
development of cholangiocarcinoma [4,[5,[6,[7,[8,[9,[10,[11]. A randomized controlled 
trial testing 17 to 23 UDCA mg/kg/day demonstrated a favorable biochemical trend but 
lacked significant effects on hard clinical endpoints including transplant-free survival 
since the study was probably underpowered [10]. Testing even higher doses (28-30 
mg/kg/day) in PSC patients revealed overall improvement in serum liver tests but were 
associated with higher risk for death, need for liver transplantation, and increased rates 
of serious adverse events [11]. Interestingly, a study on the effects of UDCA withdrawal 
in PSC patients showed significant deterioration of liver biochemistry and symptoms 
within 3 months [12]. Taken together, effective medical therapy for PSC is still an unmet 
clinical need and novel drugs are urgently needed [2]. 
 
24-nor-ursodeoxycholic acid (norUDCA) is a side-chain-shortened C23 homologue of 
UDCA and was previously shown to be highly effective in preclinical mouse models of 
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cholestatic and fibrotic liver diseases [13,[14,[15,[16,[17]. Comparing the therapeutic 
effects of UDCA and norUDCA in Abcb4 knockout mice (Abcb4-/-) as a model for 
sclerosing cholangitis and biliary fibrosis revealed specific and superior anti-
inflammatory, anti-fibrotic, and anti-proliferative effects of norUDCA [14,[15,[16]. The 
relative resistance of norUDCA to N-acyl-amidation with taurine or glycine leads to 
cholehepatic shunting of norUDCA meaning that unconjugated norUDCA as a weak acid 
can be reabsorbed by cholangiocytes, returns to the sinusoids and hepatocytes via the 
periductular capillary plexus, and is re-secreted into bile [13,[18,[19,[20,[21].  This 
process of cholehepatic shunting results in ductal targeting and leads to profound 
stimulation of cholangiocellular bicarbonate secretion and consequently induction of 
bile acid-independent bile flow and flushing of bile ducts. In addition, biliary bicarbonate 
secretion may protect cholangiocytes as bicarbonate umbrella [22] against their rather 
unfriendly environment where they have to continuously face millimolar concentrations 
of potentially toxic bile acids on their apical surface membrane [23]. Moreover, norUDCA 
and its metabolites when secreted into human bile are present in mostly monomeric 
rather than micellar form, enhancing its osmotic effect thus making norUDCA a highly 
potent choleretic drug [18].  These favorable mechanisms of norUDCA and excellent 
tolerability in phase 1 studies prompted us to initiate a multicenter placebo-controlled 
phase-2 clinical trial (NUC-3/PSC) to (i) evaluate the efficacy of three doses of norUDCA 
vs. placebo, (ii) identify efficacious norUDCA dose(s) for further evaluation in a future 
phase-3 clinical trial, and (iii) to study safety and tolerability of norUDCA.  
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Study Design and Patients 
 
This study was designed as European multicenter, double blind, randomized, placebo-
controlled, comparative, and exploratory phase-2 dose finding trial with four treatment 
groups. The overall study design is summarized in Fig. 1. Patients were randomized to 
500 mg/d, 1000 mg/d or 1500 mg/d norUDCA or placebo at 38 centers from 12 
countries. Since the therapeutic efficacy of UDCA in PSC is unclear it seemed justified to 
introduce a placebo-arm. UDCA was therefore discontinued at least 8 weeks prior to 
baseline visit in 113 of 161 patients enrolled. From 159 patients receiving the study 
medication 40 were documented as UDCA-naïve, 58 classified as UDCA responders, and 
55 as UDCA non-responders. Response was defined as (partial) normalization of serum 
ALP at the investigator’s discretion (Table 2) and this study therefore lacks a strict 
definition of UDCA response. Importantly, all UDCA exposed patients discontinued UDCA 
at least for 8 weeks prior to study inclusion. The biochemical patterns following 
discontinuation of UDCA were in line with a previous report [12] showing an increase in 
alkaline phosphatase (+27% in UDCA responder, + 15% in UDCA non-responders). A 12-
week treatment phase was followed by a 4-week follow-up period. The trial was 
performed between January 2013 and September 2015 following the principles of good 
clinical practice and in accordance with the ethical principles of the Declaration of 
Helsinki, was registered with EudraCT (No. 2011-002754-31), and approved by the 
independent local ethics committees responsible for the participating investigators.   
 
All patients provided written informed consent. Male or female PSC patients aged ≥ 18 
and < 80 years were included. PSC was verified by 2 of the 3 following criteria: (i) 
chronic cholestatic liver disease of at least 6 months duration; (ii) retrograde, operative, 
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percutaneous, or magnetic resonance cholangiography demonstrating intrahepatic 
and/or extrahepatic biliary duct changes such as beading or narrowing consistent with 
PSC within 1 year prior to baseline or (iii) liver biopsy available for review and 
compatible with the diagnosis of PSC. ALP had to be elevated ≥ 1.5 x ULN at baseline, 
Both PSC patients with or without IBD were included. Patients without a definite 
diagnostic exclusion of IBD required a colonoscopy with segmental biopsies prior to the 
baseline visit. Women of childbearing potential had to apply a highly effective method of 
birth control.  
 
Key exclusion criteria included history or presence of other concomitant liver diseases 
such as secondary sclerosing cholangitis, primary biliary cholangitis, cholangiocellular 
carcinoma, hepatitis B or C infection, Wilson’s disease, haemochromatosis, autoimmune 
hepatitis, chronic alcoholic consumption (daily consumption >30g/d), or biopsy proven 
NASH. Child Pugh score B/C liver cirrhosis and patients with history or presence of 
hepatic decompensation were excluded. In addition, patients receiving 
immunosuppressive drugs, chlorambucil, pentoxyfylline, penicillamine, pirfenidone, 
fibrates, biologicals (e.g. anti-tumor necrosis factor-α therapy), or rifampicin treatment 
3 months prior to baseline were also excluded. Endoscopic treatment for bile duct 
stenosis needed or planned within 5 months post randomization date and treatment for 
dominant bile duct stenosis within 6 months prior to baseline visit also excluded study 
participation. Moreover, patients with a total bilirubin > 3.0 mg/dl (> 50 μmol/L), at 
screening or baseline or rise in total bilirubin by at least 50% within the last 6 months 
prior to baseline were excluded from this trial.  
 
Patients were to take norUDCA 250 mg capsules for oral use; group A: 2 x 250 mg 
capsules norUDCA, group B: 4 x 250 mg capsules norUDCA, group C: 6 x 250 mg capsules 
  
Fickert et al., 12 
 
norUDCA, group D: 0. All patients were to take 6 capsules altogether (verum + placebo) 
in the morning to guarantee the blinding. The appearance, size, and taste of the placebo 
capsules for oral use were indistinguishable from the verum capsules. 
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Study assessments 
 
After randomization patients were monitored at baseline visit, interim visits at weeks 2, 
4, 6, and 8, end of treatment (EOT) at week 12, and follow up visit at week 16 (Fig. 1). At 
all visits vital signs, weight, electrocardiography and body temperature were controlled 
and laboratory assessments included routine serum biochemistry (ALT, AST, γ−GT, AP, 
total and conjugated bilirubin, albumin, CRP, total protein, serum creatinine, lipase 
LDH), hematology (blood count and differential blood count), and blood coagulation 
tests (INR, PTT). Abdominal ultrasound examination was done at screening visit and 
EOT and evaluated liver size and echogenicity, the bile duct system, gall bladder 
abnormalities, portosystemic collaterals, spleen size, and any other abnormalities. 
Patients suffering from ulcerative colitis were asked to start a diary one week before 
baseline until the EOT visit to record the four sub-scores number of stools, blood in or 
on stool, general wellbeing, and abdominal pain/cramps. The clinical activity index (CAI) 
according to Rachmilewitz was calculated by the eCRF based on the data of the patient’s 
diary at each visit. Pruritus was assessed by visual analogue scale (VAS) by making a 
vertical line from no itching (0) to unbearable itching (100). Fatigue was assessed by 
questionnaire adapted from the PBC-40 questionnaire [24]. Each item was scored on a 
5-point scale and the fatigue score was calculated as the sum of scores for the eleven 
items. To assess the physician`s general overall clinical impression of the therapeutic 
effect and changes in the patient`s condition the physician’s global assessment (PGA) 
scale was used [25]. The short health scale (SHS) is a simplified four-item questionnaire 
and was used for testing the patients’ quality of life [26]. Compliance was recorded by 
counting the returned daily boxes for study medications. Adverse events (AEs) 
representing any unfavorable and unintended sign and symptom including abnormal 
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laboratory findings were recorded at each control visit. Treatment-emergent AEs were 
defined as any event with the start of medication and occurring within the period of 
treatment. Serious adverse events (SAEs) included death, any life-threatening event, 
requirement for in-patient hospitalization or prolongation of existing hospitalization, 
events with persistent or significant disability/incapacity, and congenital anomaly/birth 
defects.  
 
Study endpoints 
 
The primary efficacy variable in this clinical trial was the relative change (%) in ALP 
between the baseline visit and the EOT visit (LOCF), since serum ALP is a relevant 
surrogate marker for prognosis in PSC patients [27,[28,[29]. This was calculated for 
each patient as follows: 100 x (ALP [LOCF] – ALP [baseline]) / ALP [baseline]. A value of -25% 
calculated for a patient means a reduction by 25%, i.e. the ALP value at EOT was three 
quarters the value that was measured at the baseline visit. Secondary efficacy endpoints 
included an at least 50% reduction in ALP between baseline and EOT; normalization (< 
upper limit of normal, ULN) or partial normalization (< 1.5 x ULN) of ALP, absolute and 
relative changes of ALP, γ-GT, AST, ALT, and serum bilirubin levels (total bilirubin and 
conjugated bilirubin) at each study visit (screening to follow-up), absolute and relative 
changes of course of pruritus measured by VAS, course of fatigue, success and 
therapeutic benefit according to PGA.   
 
Statistical Methods 
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The primary efficacy variable was subject to a confirmatory statistical analysis 
(p= 0.025, one-sided) in the context of a two-stage group-sequential adaptive study 
design. The sample size has been chosen to ensure adequate power to detect absolute 
differences in the mean relative change (%) in serum AP of about 20%. Differences of 
this magnitude were regarded to be clinically meaningful in this proof of concept study. 
The sample size required was calculated using nQuery Advisor 6.01. This was done for 
an effect size of 0.20/0.25= 0.8 and a power of 80%, with the result that 39 patients per 
treatment group were required. This calculation did not yet take the group-sequential 
adaptive study design into account. The study was conducted according to a 2-stage 
group-sequential test design with possible sample size adaptation at the interim 
analysis. To preserve the overall (experiment-wise) one-sided type I error rate of α = 
0.025 in the analysis of the primary endpoint, boundaries calculated according to 
O'Brien and Fleming were applied with a critical value at the final analysis of 2.015, and 
the inverse normal method of combining p-values was used with prospectively planned 
information rates 0.75 and 1.0 [30] at the interim analysis and at the final analysis, 
respectively. This means that a sample size of 40 patients per treatment group was 
adequate (40/39=1.0256). The planned sample size was therefore 160 patients (1:1:1:1 
randomization, i.e. about 40 patients per treatment group) in the full analysis set (FAS) 
if the study was completed without modification following the interim analysis, which 
was planned after and performed based on 120 FAS patients (about 30 per group). After 
the interim analysis no sample size adaption was required. The primary efficacy 
endpoint in this clinical trial was the mean relative change (%) in serum ALP levels 
between the baseline visit and the EOT visit. The absolute change from baseline to a visit 
and to the EOT visit was calculated as the value at the visit minus the baseline value. 
Comparisons between treatment groups were performed in two steps: The first analysis 
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step compared each norUDCA treatment group against placebo, the second analysis step 
was used for pairwise comparisons among the three norUDCA treatment groups. Only if 
all three hypotheses of the first step had been rejected, the second step was to be 
performed in a confirmatory sense. In order to adjust for multiplicity within each 
analysis step, a closed testing procedure using Simes intersection tests [31] was applied 
for each step. The inverse normal procedure was applied to Simes adjusted p-values. 
Corresponding p-values were combined, i.e. the p-value for the global hypothesis based 
on patients included in the interim analysis was combined with the p-value based on the 
remaining patients, the pairwise intersection p-values were combined with their 
counterparts, and the p-values for the elementary hypotheses were combined as well. 
The global hypothesis (intersection of the 3 elementary hypotheses) could be rejected if 
the global test statistic (FAS) resulting from the inverse normal method exceeded the 
critical value. In this case, it was to be determined which of the elementary hypotheses 
could be rejected by the closed testing procedure. One-sided p-values for the analysis of 
the primary endpoint were calculated using Wilcoxon rank sum tests. Calculations were 
performed using SAS® (version 9.3, SAS Institute, USA) and using ADDPLAN® (licensed 
by ADDPLAN, Inc., an ICON Clinical Research, LLC company). Descriptive statistical 
methods were used to analyze all variables. Continuous variables are summarized using 
the number of observations, arithmetic mean, and standard deviation. Categorical data 
are described using absolute and relative frequencies. There was no considerable 
number of centers contributing at least 3 patients per treatment group. Therefore, a 
possible center effect was not explored. A possible effect of geographical cluster was 
explored by presenting descriptive summary statistics for the primary efficacy endpoint 
stratified by geographical cluster. The following geographical clusters were used: 
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Austria, Germany, Hungary, United Kingdom, Scandinavia (Denmark, Finland, Norway, 
Sweden), Benelux (Belgium, The Netherlands), and other countries (Lithuania, Spain).  
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Results 
 
In total 231 screenings were performed in 222 patients. Out of 222 screened patients 61 
patients were not eligible for randomization. The remaining 161 patients were 
randomized. The main reason for screening failure was violation of inclusion or 
exclusion criteria in 51 patients. The study flow chart and additional reasons for 
screening failure are given in Fig. 2. Data of screening failures and data of two patients 
who did not take the study medication (one was withdrawn because of lack of 
cooperation, the other because of violation of an exclusion criterion after 
randomization) were not included in the statistical analysis.  Consequently 159 received 
the study medication comprising the intention to treat (ITT) analysis population. Out of 
the 159 patients who were treated with study medication, 21 patients discontinued the 
treatment phase prematurely (norUDCA 500 mg: 10, 25.6%; norUDCA 1000 mg: 4, 9.8%; 
norUDCA 1500 mg: 3, 7.7%, placebo: 4, 10.0%). The most frequent primary reason 
therefore were violation of inclusion or exclusion criteria (coming to light after 
randomization) or intake of prohibited concomitant medication. The number of patients 
terminating the treatment phase because of lack of efficacy was 1 in norUDCA 500 mg, 0 
in norUDCA 1000 mg, 1 in norUDCA 1500mg, and 2 in the placebo group. 
 
Patient characteristics. The main baseline characteristics of the 159 patients treated 
are shown in Table 1. Overall and for each treatment group, the majority of patients was 
male (109/159; 68.6%) reflecting the natural gender distribution in PSC patients.  There 
was no significant difference between study groups in regard to age, weight, height, BMI, 
and ALP serum levels at baseline indicating that the four treatment groups were well 
balanced at enrollment. The number of newly diagnosed PSC ranging from 6 to 8 
patients was comparable between the different treatment groups and in the range of 
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15% and 20% (Table 1) with the highest percentage in the placebo group. The rate of 
concomitant IBD was highest within the norUDCA 500 mg group (77%) and lowest 
within the placebo group (50%), however this difference did not reach statistical 
differences. There was no correction for IBD presence with respect to allocation to 
treatment groups. In the active treatment groups the median time since first symptoms 
of IBD was about 13.5 years, and the median duration of IBD disease was about 11.5 
years (Table 1).  The median duration of PSC was 6.9 years in the placebo group and 6.9, 
3.7, and 4.3 years in the 500, 1000, and 1500 mg norUDCA group respectively (variation 
not greater than expected by chance). Serum ALP values were profoundly elevated at 
baseline in all treatment groups ranging from 369 IU/L in the norUDCA 1000 mg group 
to 495 IU/L in the norUDCA 500 mg group indicating that all treatment groups had 
pronounced cholestasis. Out of 159 study patients 113 (71.0%) were UDCA experienced, 
58 (51.3%) of these were UDCA responders defined by partial normalization of ALP at 
investigator’s discretion and 55 (48.7%) UDCA non-responders. 40/159 (25,2%) were 
UDCA naїve, the response to previous UDCA treatment was unknown or not applicable 
for the remaining 6/159 (3,8%) randomized patients (Table 1). In the active treatment 
groups the proportion of UDCA non-responders ranged between 51.8% in norUDCA 
1500 mg group and 54.8% in the norUDCA 1000 mg group, whereas in the placebo 
group only 33.3% were UDCA non-responders as defined according to the investigators’ 
discretion (and therefore lacking a universal definition). The UDCA doses were in a 
similar range (between 12 and 15 mg/kg/d) in UDCA responders and non-responders 
(Table 1). There was no difference between the groups in regard to current pruritus or 
previous pruritus episodes reported by patients ranging from 40.0% in the placebo 
groups to 64.1% in the norUDCA 500 mg group. Fatigue at baseline was reported from 
45.0% in the placebo group up to 70.7% in the norUDCA 1000 mg group.  
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NorUDCA significantly reduces serum ALP levels in a dose dependent fashion in 
PSC patients. The relative reduction of serum ALP values was chosen as primary 
endpoint for this study, since ALP levels currently represent the best available surrogate 
parameter for PSC patients and therefore appeared most suitable for this short-term 
study [27,[28,[29]. In each norUDCA group the relative reduction of serum ALP was 
statistically significantly superior to placebo in the analysis of the primary endpoint 
showing dose dependent reductions by -12.3%, -17.3%, and -26.0% in the 500, 1000, 
and 1500 mg/d norUDCA groups respectively (Fig. 3). Thus, the study was positive on 
ITT for all norUDCA treatment groups. Statistically significant differences compared to 
placebo were also seen for all three norUDCA groups in the PP set (data for per protocol 
analysis not shown). Possible confounding effects of geographical clusters were not 
detected by stratified analysis of the relative reduction of serum ALP (data not shown). 
The percentage of treated patients reaching prognostically meaningful reductions of 
ALP defined as serum levels ≤ 1.5-fold the ULN [27,[28] was 12.5% (5/40) in the 
placebo group, 12.8% (5/39) in the norUDCA 500 mg group, 41.5% (17/41) in the 1000 
mg group (the group starting with the lowest ALP levels), and 30.8% (12/39) in the 
1500 mg group. ALP levels within ULN were found in 2/40 (5.0%) of the placebo group, 
1/39 (2.6%) of the norUDCA 500 mg group, 5/41 (12.2%) in the 1000 mg group, and 
4/39 (10.3%) of the 1500 mg group. Moreover, all three norUDCA doses induced a rapid 
decrease in serum ALP levels within 4 weeks, which was again most pronounced in the 
highest norUDCA treatment group (Fig. 4A). A post-hoc analysis with respect to the 
daily norUDCA dose/kg BW confirmed the main result of this study as well as a dose 
selection for the phase 3 program (data not shown). Serum ALP levels remained 
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relatively stable throughout the treatment period in the norUDCA treatment arms, but 
returned nearly to baseline levels at the end of the follow-up period indicating a 
pronounced rebound of serum ALP levels following discontinuation of norUDCA 
treatment. In contrast, in the placebo group ALP levels increased 1.2% during the study 
period until EOT (Fig. 3). Interestingly, ALP serum levels decreased in the placebo group 
from EOT to the follow up visit. This could at least in part be related to more frequent 
reintroduction of UDCA treatment in the placebo arm (9/40 = 22.5% patients; versus 
4/39 = 10.3% norUDCA 500mg; 2/41 = 4.9% norUDCA 1000mg; 5/39 = 12.8% norUDCA 
1500mg) following the active treatment period upon physician’s discretion. It may also 
be of interest to note that 8 out of these 9 patients were classified as UDCA responders 
before study entry and that the proportion of patients receiving UDCA after placebo in 
the follow-up period was about double the number in the active treatment groups 
(Supplementary Table 1). Serum bilirubin levels did not significantly differ between 
treatment groups at different time points (Supplementary Table 2). 
 
NorUDCA significantly reduces γ−GT, ALT, and AST serum levels in PSC patients.  
NorUDCA also significantly reduced serum γ−GT levels in a clearly dose-dependent 
fashion, and was most pronounced with a mean reduction of 33.9% in the norUDCA 
1500 mg group (for absolute values see Fig. 4B). Notably, the dose-dependency of the 
biochemical norUDCA effects in the reduction of serum enzyme levels was most 
apparent for serum γ−GT compared to the other serum parameters (Fig. 4). In parallel 
to reduction of the cholestatic liver enzymes, the median reduction of serum AST levels 
was 20.5% and 33.1% in ALT levels at EOT (for absolute values see Fig. 4C and D, 
respectively). As observed for ALP, following a significant reduction under norUDCA 
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treatment, a pronounced rebound of γ−GT, AST, and ALT serum levels was evident from 
EOT to the follow up visit.  
 
norUDCA response is not predicted by previous UDCA treatment, previous UDCA 
response, presence of IBD, or duration of PSC. Importantly, a dose-dependent 
reduction of ALP was observed in both sexes and independent of previous UDCA-pre-
treatment and response (Table 2). Similarly, presence of IBD, duration of PSC and 
baseline ALP levels had no impact on the dose-dependent response to norUDCA (Table 
2). Notably, the percentage of patients without therapeutic response to norUDCA 
(defined as an ALP at EOT above screening values when most patients were still on 
UDCA) declined sharply with increasing norUDCA doses, again independently of 
previous UDCA pre-treatment and response (Supplementary Fig. 1).  
 
Patient related outcomes. Body weight, body temperature, and vital signs did not 
show any relevant changes from baseline to EOT in all four treatment groups. It is 
interesting to note, that 7 (17.9%) patients showed enlarged spleen at baseline in the 
norUDCA 500 mg group, 3 (7.3%) in the 1000 mg group, and 3 in the 1500 mg group. At 
EOT this number was reduced to 4 (10.3%), 0, and 0 patients in each verum-treated 
group respectively, while the number of patients with enlarged spleen was 2 (5%) in the 
placebo group at baseline and increased to 3 (7.5%) EOT. The mean values of sum of CAI 
were low in all treatment groups at baseline and EOT (1.3/1.7 norUDCA 500 mg group, 
0.9/1.0 1000 mg group, 2.0/1.3 1500 mg group, and 2.1/1.5 in the placebo group). The 
sub-scores with the highest mean values at baseline were score for number of stools, 
score for general wellbeing, score for bloody stools, score for abdominal pain/cramps 
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and laboratory findings. Sub-scores showed some variability but no trend among 
treatment groups. In addition, there was no statistical significant difference in SHS 
scores between treatment groups but indicated a slight improvement from baseline to 
EOT for the norUDCA 1500 mg group for each individual dimension. Using the sum of 
eleven questions for the calculation of the fatigue score there was no significant 
difference from baseline (placebo 23.0, norUDCA 500 mg 21.0, 1000 mg 19.7, 1500 mg 
23.3) to EOT (placebo 21.3, norUDCA 500 mg 20.7, 1000 mg 19.8; 1500mg 20.2) and 
between treatment groups. However, a slight improvement of symptoms according to 
physician’s global assessment (PGA) of efficacy could be achieved at EOT for 43.6% of 
patients in the 1500 mg norUDCA group, 29.3% in the 1000 mg, 23.1% in the 500 mg, 
and 30% in the placebo group. These differences did not reach statistical significance.  
 
NorUDCA showed a favorable safety profile. Tolerability of the study medication was 
assessed as very good in the vast majority of patients by both the patients and 
investigators. A poor tolerability was expressed only by 2 patients (4.9%) in the 
norUDCA 1000 mg group and by 1 patient (2.5%) in the placebo group. Tolerability was 
assessed as equally good in all treatment arms. No patient died during the course of this 
study. The percentage of treatment emergent AEs was 80%, 59%, 73%, and 67% in the 
placebo group, for the norUDCA 500 mg, the norUDCA 1000 mg group, and norUDCA 
1500 mg groups respectively. In total 8 treatment-emergent SAEs were noted in 8 
patients, 3 in the norUDCA 500 mg group, 1 in the norUDCA 1000 mg, 1 in the 1500 
norUDCA group, 3 in the placebo group. The number of treatment emergent SAEs was 
therefore similar between treatment groups. Only one SAE in the placebo group was 
assessed by an investigator as possibly related to IMP (ocular icterus/lack of clinical 
efficacy). Additional five SAEs not related to treatment were also categorized as “disease 
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progression/lack of clinical efficacy”. The remaining two SAEs were a removal of 
meniscus and a diagnosis of colon cancer 4 days after start of treatment. Treatment 
emergent AEs reported in more than 10 patients were abdominal pain (11) fatigue (13), 
nasopharyngitis (30), headache (13), and pruritus (17).  Differences of the incidence 
between treatment groups did generally not show dose-dependent effects, also not 
compared to placebo. In general, the safety profile of norUDCA was unremarkable and 
did not differ from placebo. In addition, the percentage of adverse drug reactions was 
comparable in all groups with 28%, 23%, 32%, and 28% in the placebo group, for the 
norUDCA 500 mg, the norUDCA 1000 mg, and norUDCA 1500 mg groups respectively. 
The most common adverse events with the most prominent being nasopharyngitis in all 
treatment groups are listed in Table 3. Notably, also pruritus occurred at similar and all 
over at low frequencies as adverse event: 7 events in the 500 mg/d-, 7 in the 1000 
mg/d-, 12 in the 1500 mg/d-group and 10 in the placebo group. Importantly pruritus 
was mild and no patient discontinued treatment. There were no significant differences 
of scores for pruritus between at baseline (placebo 15.4, 500 mg 9.9, 1000 mg 14.8, 
1500 mg 16.5; scale 0-100 mm) and at EOT (placebo 15.3, 500 mg 10.8, 1000 mg 20.9, 
1500 mg 15.2) and between all treatment groups. There was no effect on IBD activity. 
Taken together the safety profile of norUDCA seems to be favorable and no warning 
signal emerged from the data of this study.  
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Discussion 
 
 
For decades there has been no significant progress in the medical therapy of PSC. This 
double blind, randomized, placebo-controlled, dose finding study is a proof of concept 
study and the first human study with norUDCA to assess efficacy, safety and tolerability 
in PSC patients. The main findings of the study are: (i) norUDCA resulted in a significant 
reduction of ALP values in PSC patients within 12 weeks of treatment compared to 
placebo, (ii) the positive effects occurred in a dose-dependent manner, and (iii) the 
safety profile of norUDCA was comparable to placebo in our study.  
 
All three norUDCA doses tested in this study resulted in a significant reduction in ALP, 
which was most pronounced in the 1500 mg arm and consequently all norUDCA 
treatment arms reached the primary efficacy endpoint at ITT analysis as defined for this 
study. In addition, ALP decline was paralleled by significant reductions in ALT, AST, and 
γ−GT levels. In particular the time course of γ−GT levels uncovered the most pronounced 
relationship between norUDCA doses and biochemical effect. In addition to serving as 
biochemical parameter of cholestasis in PSC patients, serum γ−GT levels may also reflect 
inflammation-triggered hepatic oxidative stress [32,[33,[34], which may be significantly 
reduced upon norUDCA treatment as observed previously in preclinical models 
[14,[15,[16,[17]. Since spleen size may also reflect PSC activity [35] it is worthwhile 
mentioning that 13 verum-treated patients showed increased spleen size at baseline but 
only 4 at EOT; however potential anti-inflammatory effects of norUDCA need detailed 
future mechanistic studies. Interestingly patients in the placebo arm showed a decrease 
of all serum parameters tested in the follow-up period of the study comparable to the 
effect of norUDCA in the verum group, which may be primarily related to the more 
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frequent reintroduction of UDCA treatment in this study group of patients who 
continued to show profoundly elevated cholestasis parameters throughout the 
treatment period after discontinuation of UDCA in the prestudy washout phase. It is also 
important to note that the most pronounced relative decrease in serum ALP levels was 
observed in the 1500 mg norUDCA group with a 26 % reduction indicating a dose-
dependent effect of norUDCA. This observation is also relevant for dose selection of 
future phase III clinical trial in PSC patients, since the 1500 mg norUDCA was also well 
tolerated. Importantly 12.8 % achieved a reduction of serum ALP levels ≤ 1.5 x the ULN 
in the norUDCA 500 mg group, 41.5 % in the 1000 mg norUDCA group, 30.8 % in the 
1500 mg norUDCA group, and 12.5 % in the placebo group, which was previously shown 
to be of potential prognostic importance in PSC patients [28,[36,[37].  
 
Although a direct comparison of the current study with previous UDCA trials in PSC is 
not possible due to substantial differences in study design, UDCA has also demonstrated 
pronounced ALP reduction in the range observed for norUDCA herein or even higher 
[6,[38,[39]. Along these lines it is also important to note that in the post-hoc analyses of 
the very high dose UDCA trials as reported by Stanich et al. [27] and of the Scandinavian 
UDCA trial by Lindström et al. [40] patients with normalization of ALP had a better 
prognosis although this was not necessarily related to UDCA use. This may underscore 
the prognostic relevance of ALP normalization in PSC patients, but also points towards a 
potential dissociation from active drug (UDCA) treatment. Importantly, based on our 
preclinical findings norUDCA can be expected to have profoundly different / additional 
mechanisms than UDCA which may not be fully reflected by biochemical improvement 
in short term phase II studies. For our current study it is essential to note that the 
observed response to norUDCA treatment was independent of whether patients were 
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UDCA-naïve or -experienced on one hand and whether the physicians categorized them 
as UDCA non-responder or responders. There may however still be PSC patients, which 
may benefit from UDCA treatment, namely potentially those with significant reduction 
in ALP serum levels. Interestingly norUDCA-induced fall in serum ALP levels was most 
pronounced within the first two weeks of treatment.  Consequently, it appears plausible 
that norUDCA may reduce the viscosity of bile immediately after starting the treatment, 
since it represents a potent pharmacological inducer of biliary bicarbonate secretion 
and therefore protects the liver [41]. 
 
The safety profile of norUDCA as observed in our study was very encouraging. Most 
importantly there was no statistical difference in regard to treatment emergent adverse 
events between norUDCA and placebo arms. The most frequently reported complaints 
were related to nasopharyngitis, which was also comparable between all treatment 
arms.  The number of reported SAEs was generally low and equally in all treatment 
arms. Consequently the reported adverse events reported in this study showed no 
warning signal for norUDCA treatment in PSC patients. This is particularly important for 
pruritus, which was not more frequently observed in the norUDCA arms, since pruritus 
may represent a serious problem associated with bile acid treatment in cholestatic 
patients [42,[43,[44]. We did not observe any significant differences in regard to fatigue 
score, CAI, and physician’s global assessment between baseline and EOT in all treatment 
arms. However, it may be overambitious to expect significant differences within 12 
weeks norUDCA treatment; notably we also observed no worsening in these scores, 
which indicates at least that norUDCA was well tolerated in all active treatment arms. 
Importantly this first in patients norUDCA study excluded patients with main bile duct 
strictures or recent need for endoscopic therapy, since we had potential concerns 
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regarding the potent choleretic actions of norUDCA observed preclinically [23] (14,15). 
Predicting the relative risk for potential aggravation of portal hypertension or the 
development of bile infarcts in norUDCA-treated PSC patients with more advanced 
disease or main bile duct strictures will be very challenging. This may become even 
more complex when combination therapy of norUDCA with UDCA is considered in future 
studies, since the compounds may have additive beneficial effects [23] Therefore closely 
spaced, clinical, and biochemical controls will be necessary for the best safety of our 
patients in a future phase III clinical trial. 
 
This norUDCA phase II dose finding study in PSC has several limitations including the 
lack of C4 bile acids and FGF19 serum levels. The primary efficacy variable of this phase 
II clinical trial was defined as the relative change (%) in serum ALP between the 
baseline visit and the EOT since ALP, transient elastography, and histology are currently 
seen as the most promising candidate surrogate endpoints for clinical trials in PSC 
[29,[36,[45,[46]. However, pronounced changes in liver stiffness or liver histology may 
be rather ambitious to expect within a short treatment period for 12 weeks in PSC 
patients and therefore have not been chosen as primary endpoints for this study. 
Moreover, the observed significant reduction in ALP values in all norUDCA treatment 
arms in our study should not be overestimated at this stage. A randomized controlled 
trial testing high doses of UDCA (17 to 23 mg/kg/day) showed a favorable biochemical 
trend but lacked significant effects on hard clinical endpoints such as transplant-free 
survival and was in addition probably underpowered [10]. Testing even higher doses 
(28-30 mg/kg/day) in PSC patients again revealed improvement in serum liver tests 
including ALP but were associated with adverse clinical outcomes [11]. In the current 
study PSC patients with more advanced disease namely Child’s Pugh class B and C and 
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those with serum bilirubin levels higher 3 mg/dL have been excluded due to potential 
safety reasons. Consequently, it is currently unclear whether norUDCA will be also safe 
in such patients.   
 
In summary, the herein presented findings justify a phase III clinical trial for norUDCA 
treatment in PSC patients. The design of such a trial poses several key questions: (i) A 
future study should consider combined end-points with serum ALP levels, transient 
elastography, properly assessment of spleen size, and liver histology, since hard clinical 
end-points such as need for liver transplantation or death will be unrealistic study end-
points for such a rare disease with a highly variable clinical course. (ii) The different 
therapeutic mechanisms and pharmacodynamics of norUDCA and its mother compound 
UDCA may provide a potential rationale for combining norUDCA and UDCA in the 
treatment in PSC, which has to be demonstrated in a combination therapy arm. (iii) 
Based on our current data the daily norUDCA dose of 1500 mg was proven to be 
efficacious and safe and should be further tested in a phase III clinical trial.   
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Table 1: Demographic and baseline characteristics of randomized and treated patients. 
 
 
 
Placebo 
(N=40) 
norUDCA 
500mg 
(N=39) 
norUDCA 
1000mg 
(N=41) 
norUDCA 
1500mg 
(N=39) 
Male  
Female  
N (%)         
N (%) 
25 (62.5%) 
15 (37.5%) 
27 (69.2%) 
12 (30.8%) 
28 (68.3%) 
13 (31.7%) 
29 (74.4%) 
10 (25.6%) 
Age (y) Mean (SD) 44.1 (14.89) 40.9 (12.24) 42.3 (13.08) 41.0 (13.11) 
Weight (kg) Mean (SD) 78.7 (13.63) 75.5 (13.51) 79.1 (15.37) 77.7 (15.65) 
Height (cm) Mean (SD) 176.0 (12.14) 176.0 (9.01) 175.7 (8.06) 176.9 (11.30) 
BMI (kg/m2) Mean (SD) 25.5 (3.93) 24.3 (3.87) 25.6 (4.94) 24.8 (3.78) 
Duration of PSC 
(Months) 
Median 
(Range) 
83 (2-343) 83 (1-345) 45 (2-242) 52 (2-311) 
New diagnosis 
of PSC            
N (%) 8 (20.0%) 6 (15.4%) 8 (19.5%) 7 (17.9%) 
IBD at screening    
Ulcerative colitis    
Crohn‘s disease    
 
N (%)            
N (%) 
50% 
15 (37.5%) 
5 (12.5%) 
77% 
27 (69.2%) 
3 (7.7%) 
65% 
22 (53.7%) 
5 (12.2%) 
64% 
24 (61.5%) 
1 (2.6%) 
Time since first IBD 
symptoms 
(Months) 
Median 
(Range) 
162 (36-451) 183 (10-416) 151 (4-526) 140 (11-476) 
ALP at baseline (U/L)                                                                                                                        Mean (SD) 456 (234.4) 495 (282.4) 369 (200.6) 464 (241.6) 
UDCA naïve N (%) 12 (30.0%) 9 (23.1%) 9 (22.0%) 10 (25.6%) 
UDCA pre-treatment N (%) 27 (67.5%) 28 (71.8%) 31 (75.6%) 27 (69.2%) 
     Responder 
     Mean previous dose 
N (%) 
mg/kg/d 
18 (66.7%) 
14.5 
13 (46.4%) 
13.7 
14 (45.2%) 
12.2 
13 (48.2%) 
13.3 
     Non-responder 
     Mean previous dose 
N (%) 
mg/kg/d 
9 (33.3%) 
14.3 
15 (53.6%) 
13.0 
17 (54.8%) 
14.4 
14 (51.8%) 
15.3 
Unknown UDCA 
exposure 
N (%) 1 (2.5%) 2 (5.1%) 1 (2.4%) 2 (5.1%) 
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Table 2.  Relative changes (%) in ALP serum levels from baseline to EOT according to 
UDCA pretreatment as well as UDCA treatment response and other clinical parameters 
 
 
Placebo 
(N=40) 
norUDCA 
500mg 
(N=39) 
norUDCA 
1000mg 
(N=41) 
norUDCA 
1500mg 
(N=39) 
Male Mean % (N) +4.7% (25) -14.1% (27) -13.9% (28) -27.8% (29) 
Female Mean % (N) -4.6% (15) -8.3% (12) -24.7% (13) -20.5% (10) 
UDCA responder Mean % (N) 
 
- 6.2% (18) 
 
- 9.9% (13) - 16.4% (14) - 19.5% (13) 
UDCA non-responder Mean % (N) - 3.5% (9) - 10.1 (15) - 14.9% (17) - 27.3% (14) 
 
UDCA naïve 
 
Mean % (N) +12.3% (12) - 14.9% (9) - 24.8% (9) - 32.0% (10) 
ALP <	3xULN  Mean % (N) -0.9% (25) -14.4% (23) -19.7% (17) -26.2% (22) 
ALP ≥	3xULN  Mean % (N) 4.8% (15) -9.2% (16) -15.6% (24) -25.7% (17) 
PSC with IBD Mean % (N)* 5.8% (20) -10.4% (29) -14.5% (27) -24.0% (27) 
PSC without IBD Mean % (N)* -4.8% (18) -21.8% (8) -22.8% (14) -29.9% (11) 
PSC duration	≤	5 yrs Mean % (N)** 8.3% (15) -10.5% (17) -20.3% (22) -28.2% (20) 
PSC duration	> 5 yrs  Mean % (N)** -3.0% (24) -13.7% (22) -13.4% (18) -23.7% (19) 
 
 * In N=5 no classification to IBD or non-IBD was possible; ** in N=2 not data of the first 
PSC diagnosis was documented. 
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Table 3. Most common adverse events.  
 
 
Placebo 
(N=40) 
norUDCA 
500mg 
(N=39) 
norUDCA 
1000mg 
(N=41) 
norUDCA 
1500mg 
(N=39) 
Abdominal pain 5 (12.5%) 1 (2.6%) 4 (9.8%) 1 (2.6%) 
Diarrhea 4 (10.0%) 0 (0.0%) 1 (2.4%) 3 (7.7%) 
Fatigue 4 (10.0%) 2 (5.1%) 2 (4.9%) 5 (12.8%) 
Nasopharyngitis 7 (17.5%) 6 (15.4%) 9 (22.0%) 8 (20.5%) 
Arthralgia 4 (10.0%) 1 (2.6%) 1 (2.4%) 0 (0.0%) 
Back pain 4 (10.0%) 1 (2.6%) 0 (0.0%) 3 (7.7%) 
Headache 3 (7.5%) 2 (5.1%) 1 (2.4%) 7 (17.9%) 
Pruritus 4 (10.0%) 3 (7.7%) 4 (9.8%) 6 (15.4%) 
 
Number of patients (%) with treatment emergent adverse events 
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FIGURE LEGENDS 
 
Fig. 1. Trial design of the NUC-3 PSC study. Patients were screened for eligibility and 
eligible patients were randomized in an equal ratio to either 500 mg/d, 1000 mg/d, 
1500 mg/d norUDCA, or placebo. After randomization control visits were performed at 
week 0, 2, 4, 6, 8, 10, and 12. A follow-up visit was performed 4 weeks after end of study 
(week 16). UDCA, ursodeoxycholic acid; norUDCA, norursodeoxycholic acid; wks, weeks; 
EOT, end of treatment.  
 
Fig. 2. Patient recruitment. Of 222 patients assessed for eligibility 161 were 
randomized and 159 received the study medication. ITT, intention to treat; SAE, serious 
adverse event. The sample size required was calculated using nQuery Advisor 6.01. This 
was done for an effect size of 0.20/0.25= 0.8 and a power of 80%, with the result that 39 
patients per treatment group were required. 
 
Fig. 3. Percentage change in serum levels of ALP after 12 weeks compared to 
baseline values. Serum ALP levels decreased in a dose-dependent manner in response 
to norUDCA treatment with the most pronounced reduction in the 1500 mg norUDCA 
arm. NU, norursodeoxycholic acid. * indicates p<0.01 compared to placebo; # indicates 
p<0.025 comparison of NU 1500mg vs. NU 500mg. A closed testing procedure using 
Simes intersection tests [31] was applied for each group comparison (comparison of 
each norUDCA treatment group against placebo and pairwise comparisons among the 
three norUDCA treatment groups). The inverse normal procedure was applied to Simes 
adjusted p-values. One-sided p-values for the analysis of the primary endpoint were 
calculated using Wilcoxon rank sum tests. 
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Fig. 4. Absolute changes in serum ALP, γGT, ALT, and AST levels throughout the 
study period. Y axis indicates absolute changes (U/L) compared to baseline levels. NU, 
norursodeoxycholic acid. Placebo group, open gray circles; 500mg NU group, blue filled 
circles; 1000mg NU group blue filled triangles; 1500mg NU group, blue filled squares. 
Descriptive statistical methods were used to analyze all variables. Continuous variables 
are summarized using the number of observations, arithmetic mean, and standard 
deviation. 
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Highlights 
 
• There is an urgent need for novel drugs for PSC.  
 
• In this phase II clinical trial norUDCA reduced serum ALP levels within 12 
weeks. 
 
• norUDCA effects on liver enzymes were dose-dependent.  
 
• The safety profile of norUDCA was excellent.  
 
 
